Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 28, Issue 6, Pages 1167-1177
Publisher
Springer Science and Business Media LLC
Online
2022-06-04
DOI
10.1038/s41591-022-01829-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.
- (2022) Jaclyn Paige Lyman et al. JOURNAL OF CLINICAL ONCOLOGY
- APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application
- (2021) Erin L. Filbert et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
- (2021) M. Tempero et al. ANNALS OF ONCOLOGY
- The Next Decade of Immune Checkpoint Therapy
- (2021) Padmanee Sharma et al. Cancer Discovery
- Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
- (2021) Katelyn T. Byrne et al. CLINICAL CANCER RESEARCH
- Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
- (2021) Luuk van Hooren et al. Nature Communications
- Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming
- (2021) Mark S. Diamond et al. Cancer Immunology Research
- Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
- (2021) Zhenyu Yang et al. Frontiers in Oncology
- Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
- (2020) Jean-Christophe Beltra et al. IMMUNITY
- Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
- (2020) Zev A. Wainberg et al. CLINICAL CANCER RESEARCH
- Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
- (2020) Divij Mathew et al. SCIENCE
- CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
- (2020) Mark H O'Hara et al. LANCET ONCOLOGY
- Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy
- (2019) Felix J. Hartmann et al. Cell Reports
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy
- (2018) Jinyang Li et al. IMMUNITY
- Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- Regulation of the Germinal Center Response
- (2018) Marisa Stebegg et al. Frontiers in Immunology
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
- (2017) Ingunn M. Stromnes et al. Cancer Immunology Research
- Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
- (2016) David Balli et al. CLINICAL CANCER RESEARCH
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
- (2016) Toni K. Choueiri et al. CLINICAL CANCER RESEARCH
- Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
- (2016) Takaaki Tokito et al. EUROPEAN JOURNAL OF CANCER
- CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
- (2016) Katelyn T. Byrne et al. Cell Reports
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- An interactive reference framework for modeling a dynamic immune system
- (2015) M. H. Spitzer et al. SCIENCE
- Achieving high-sensitivity for clinical applications using augmented exome sequencing
- (2015) Anil Patwardhan et al. Genome Medicine
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability
- (2014) Erika Assarsson et al. PLoS One
- Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+dendritic cells at cross presentation
- (2013) Lillian Cohn et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- Human Tissues Contain CD141hi Cross-Presenting Dendritic Cells with Functional Homology to Mouse CD103+ Nonlymphoid Dendritic Cells
- (2012) Muzlifah Haniffa et al. IMMUNITY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- (2011) Mark A DePristo et al. NATURE GENETICS
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started